Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Jan

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL

Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer

Anaplastic Glioma Concurrent vs Adjuvant Temozolomide

Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer

Refractory LBCL CD19-Targeting CAR T-Cell Therapy Plus Rituximab